Genevant and Arbutus File Global Patent Lawsuits Against Moderna

Story Highlights
Genevant and Arbutus File Global Patent Lawsuits Against Moderna

Arbutus Biopharma ( (ABUS) ) has issued an announcement.

Genevant Sciences and Arbutus Biopharma have initiated international patent infringement lawsuits against Moderna, targeting alleged unauthorized use of their LNP technology in Moderna’s products across 30 countries. The legal actions seek monetary relief and injunctions, expanding on ongoing proceedings in the U.S., and highlight the critical role of LNP technology in mRNA delivery, a field where both companies have significant expertise and investment.

More about Arbutus Biopharma

Genevant Sciences is a leading nucleic acid delivery company with a robust lipid nanoparticle (LNP) patent portfolio, specializing in RNA-based applications such as vaccines and gene editing. Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases, particularly chronic hepatitis B, and is invested in LNP delivery technology through its partnership with Genevant.

YTD Price Performance: 4.86%

Average Trading Volume: 832,905

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $653.7M

For an in-depth examination of ABUS stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App